Combining Niraparib with Abiraterone Acetate and Prednisone Significantly Improves rPFS in Patients with mCSPC Harbouring BRCA1/2 or Other HRR Gene Alterations By Ogkologos - October 22, 2025 355 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLITUDE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR ESMO Manifesto – Translating Scientific Evidence Into Effective Public Health Policy October 20, 2023 Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... July 27, 2018 Evaluation of Primary and Secondary Prevention of Oral Cancer October 28, 2022 New study to detect oesophageal cancer earlier April 28, 2022 Load more HOT NEWS Gift Giving During a Pandemic How NatWest Group are making a difference this Giving Tuesday FDA Approves Taletrectinib for ROS1-positive Non-Small Cell Lung Cancer Comme louer son affaire en compagnie de tacht mahometane? (2023)
